

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
WASHINGTON, D.C. 20549

---

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT  
TO RULE 13a-16 or 15d-16 UNDER THE  
SECURITIES EXCHANGE ACT OF 1934**

**For the month of May, 2019**

Commission File Number: 001-38452

**MEREO BIOPHARMA GROUP PLC**

(Translation of registrant's name into English)

**4<sup>th</sup> Floor, One Cavendish Place,  
London, W1G 0QE, United Kingdom**  
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

---

---

**Mereo BioPharma Group plc**

("Mereo" or the "Company")

**Notification of Director Dealing**

**London, May 03, 2019** - Merco BioPharma Group plc (AIM: MPH), a clinical stage UK based biopharmaceutical company focused on rare diseases, received notification that on 01 May 2019, John Richard, Head of Corporate Development at Merco BioPharma, purchased 3500 American Depositary Shares (ADSs) at a total price of USD5.077 per share.

The below announcement and notification is made in accordance with the EU Market Abuse Regulation. The form required under the EU Market Abuse Regulation follows.

1	Details of the person discharging managerial responsibilities															
a)	Name	John Richard														
2	Reason for the notification															
a)	Position/status	Head of Corporate Development														
b)	Initial notification/ Amendment	Initial notification														
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor															
a)	Name	Mereo BioPharma Group plc														
b)	LEI	213800U8JQHJIOS5AS09														
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted															
a)	Description of the financial instrument, type of instrument and identification code	MEREO BIOPHARMA GROUP PLC AMERICAN DEPOSITARY SHARES (ADSs)														
b)	Nature of the transaction	PURCHASE														
c)	Price(s) and volume(s)	<table><thead><tr><th>Price(s)</th><th>Volume(s)</th></tr></thead><tbody><tr><td>USD5.05</td><td>98</td></tr><tr><td>USD5.06</td><td>100</td></tr><tr><td>USD5.08</td><td>2723</td></tr><tr><td>USD5.08</td><td>100</td></tr><tr><td>USD5.08</td><td>100</td></tr><tr><td>USD5.09</td><td>126</td></tr></tbody></table>	Price(s)	Volume(s)	USD5.05	98	USD5.06	100	USD5.08	2723	USD5.08	100	USD5.08	100	USD5.09	126
Price(s)	Volume(s)															
USD5.05	98															
USD5.06	100															
USD5.08	2723															
USD5.08	100															
USD5.08	100															
USD5.09	126															
d)	Aggregated information: volume, Price	Aggregated volume: 3500 Aggregated price: USD5.077														
e)	Date of the transaction	2019-05-01														
f)	Place of the transaction	XNMS														

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: May 3, 2019

**MEREO BIOPHARMA GROUP PLC**

By: /s/ Richard Jones  
Name: Richard Jones  
Title: Chief Financial Officer

---